Cole's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2024
Question
Cole asked about addressing the clinical trial process, which he identified as the biggest bottleneck in drug development.
Answer
Najat Khan, Chief R&D and Commercial Officer, outlined a two-pronged strategy. First, for trial design, the company uses multimodal real-world data from partners like Tempus and Helix to better stratify patients and simulate trial criteria, reducing costly amendments. Second, for trial operations, she cited the use of machine learning to identify patient populations and accelerate recruitment, noting the REC-4881 program cohort was recruited in 4-6 weeks instead of the typical 4-6 months.